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Abstract: Brugada syndrome (BrS) is marked by coved ST-segment elevation and increased risk of
sudden cardiac death. The genetics of this syndrome are elusive in over half of the cases. Variants in
the SCN5A gene are the single most common known genetic unifier, accounting for about a third
of cases. Research models, such as animal models and cell lines, are limited. In the present study,
we report the novel NM_198056.2:c.1111C>T (p.Gln371*) heterozygous variant in the SCN5A gene,
as well as its segregation with BrS in a large family. The results herein suggest a pathogenic effect
of this variant. Functional studies are certainly warranted to characterize the molecular effects of
this variant.
Keywords: Brugada syndrome; sudden cardiac death; genetic testing; arrhythmia; SCN5A; sodium
channel; channelopathy; variant; mutation; humans; family; nonsense mutation; premature stop codon
1. Introduction
Brugada syndrome (BrS) is characterized by coved ST-segment elevation (type one BrS pattern)
on the electrocardiogram (ECG), which may occur spontaneously or after administration of a
sodium-channel-blocking agent such as ajmaline [1]. This syndrome is associated with an increased
risk of sudden cardiac death (SCD) [1] due to ventricular arrhythmias caused by an arrhythmogenic
substrate (AS) usually located in the right ventricular (RV) epicardium [2,3]. Diagnosis of BrS is
challenging, since the first clinical manifestation of the syndrome may be SCD (or aborted SCD), which
often occurs in early adulthood, often during sleep. Phenotypes vary greatly, even within families, and
even within the same individual in response to certain factors, such as vagal tone, fever, or drugs [4].
The genetics of BrS are elusive in the majority of cases [5], with many recent studies aimed at the
identification of possible new causative genes [6–10], while variants in the SCN5A gene account for about
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15–30% of cases [11]. However, SCN5A variants are responsible for many pathologies, such as dilated
cardiomyopathy, left ventricular noncompaction, arrhythmogenic right ventricular cardiomyopathy,
atrial fibrillation, heart block, and various other arrhythmias [4,12,13], making genotype/phenotype
predictions difficult. Therefore, recently, several studies focused on genotype–phenotype relationships
involving SCN5A variants in BrS [4,14–18].
Improving the ability to molecularly confirm (or rule out) BrS is imperative, because ajmaline testing
to identify the syndrome [19,20], as well as testing for inducibility of ventricular tachycardia/fibrillation
(VT/VF)—which may be needed to justify the use of an implantable cardioverter-defibrillator
(ICD)—often require patients to travel great distances to specialized centers [21], and the tests
can be quite costly. There are also waiting lists to have these tests performed. Some patients may
be physically unable to travel or too young to undergo ajmaline testing. Therefore, having a blood
test that can identify the syndrome would help identify especially asymptomatic family members.
However, for the majority of patients, science is currently limited, in that we need to identify other
genes that may be involved and better characterize genotype–phenotype relationships for specific
variants in genes that are already known to be associated with BrS.
In the present study, we report the novel NM_198056.2:c.1111C>T (p.Gln371*) heterozygous
variant in the SCN5A gene, its segregation with BrS in a large family, as well as evidence of pathogenicity.
2. Case Presentations
Written informed consent of human subjects included in this case series report was obtained for
their participation in the study and for publication. The procedures employed were reviewed and
approved by the local ethics committee. The study was conducted in accordance with the Declaration
of Helsinki, and written informed consent of human subjects was obtained for their participation in
the study and for publication. The procedures employed were reviewed and approved by the local
Ethics Committee (approver number: M-EC-006/A, rev. 1 March 2013).
The proband was a 39-year-old woman of Italian origin who had previously performed genetic
counseling elsewhere with a positive test for the familial heterozygous variant NM_198056.2:c.1111C>T
(p.Gln371*) in the SCN5A gene (Figure 1, LOVD: https://databases.lovd.nl/shared/variants/0000579034#
00018523). She came to our attention for a second opinion because of recurrent palpitations. She
underwent an ajmaline challenge at our hospital, which was positive, after which she had polymorphic
ventricular tachycardia. An electrophysiological study (EPS) was performed, which was positive
(Figure 2). An implantable cardioverter-defibrillator (ICD) was implanted. The proband then
underwent radiofrequency catheter ablation of the AS, which was found in the epicardium of the right
ventricular outflow tract. Ajmaline was administered prior to ablation to visualize the full extent of the
AS (Figure 3).
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Figure 1. Identification of the c.1111C>T (p.Gln371*) heterozygous nonsense mutation in the SCN5A 
gene by Sanger sequencing. The red star indicates the location of the mutation (A) Sample SL2032 (II-
4) (proband) harboring the familial variant in heterozygosis (in accordance with IUPAC 
nomenclature, “Y” is used as the ambiguous code to describe the simultaneous presence of both the 
wild type C and mutant T peaks). (B) Sample SL2033 (II-5) resulted negative for the mutation. 
 
Figure 2. Electrocardiogram (ECG) at baseline, after ajmaline administration, ventricular 
tachycardia/fibrillation (VT/VF) inducibility during electrophysiological study (EPS). (A) Proband. 
(B) Proband’s cousin, family member II-1. 
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gene by Sanger sequencing. The red star indicates the location of the mutation (A) Sample SL2032 (II-4)
(proband) harboring the familial variant in heterozygosis (in accordance with IUPAC nomenclature,
“Y” is used as the ambiguous code to describe the simultaneous presence of both the wild type C and
mutant T peaks). (B) Sample SL2033 (II-5) resulted negative for the mutation.
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Figure 3. Epicardial arrhythmogenic substrate and duration of fragmented potentials in the proband 
at baseline, after the administration of ajmaline, and after ablation. PDM: potential duration map. 
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The pedigree and a summary of the family history can be seen in Figure 4A. 
Figure 3. Epicardial arrhythmogenic substrate and duration of fragmented potentials in the proband at
baseline, after the administration of ajmaline, and after ablation. PDM: potential duration map.
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2.1. Assessment of Family Members
The pedigree and a summary of the family history can be seen in Figure 4A.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 10 
 
Figure 4. (A) Family pedigree. Proband identified with arrow. Square: male; circle: female; shaded 
background: ajmaline positive or spontaneously occurring type one Brugada syndrome (BrS) ECG 
pattern; lined bottom left corner: BrS clinically suspected; star: molecularly confirmed SCN5A variant; 
star with slash: genetic test for SCN5A variant performed but negative; y: years old at first diagnosis. 
(B) Atrioventricular nodal reentrant tachycardia of Patient III-1 detected by loop recorder. (C) Sinus 
node arrest associated with syncope in Patient III-1 detected by loop recorder. (D) Sinus node arrest 
associated with dizziness during fever in Patient III-1 detected by loop recorder. 
The proband’s father (patient I-3 on family tree, Figure 4A) was a 64-year-old male with a history 
of at least two lipothymic episodes, bradycardia, and an implanted pacemaker before 60 years of age. 
He was evaluated because of this history and because of the BrS clinical diagnosis in his elder 
daughter (the proband). He had a positive result from an ajmaline challenge, and genetic testing was 
subsequently performed, demonstrating that he was a heterozygous carrier of the mutation found in 
the proband. 
The proband’s sister (patient II-5 on Figure 4A) was a 32-year-old woman with no remarkable 
medical history. Due to the presence of BrS in her family, she underwent both a flecainide challenge 
and blood sampling for the genetic test elsewhere. Both tests were negative. 
The eldest cousin of the proband (patient II-1) had a medical history characterized by sleep 
disturbances without sleep apnea, as well as a single syncopal episode, after which she underwent 
genetic counseling. Genetic testing confirmed the presence of the familial mutation in the 
heterozygous state with maternal inheritance. For a second opinion, she was evaluated in our 
hospital, where an EPS and ajmaline test were both performed, both with positive results, resulting 
in the implantation of an ICD. 
The eldest son of patient II-1 was 14 years old. BrS was suspected due to his mother’s history of 
the syndrome combined with the presence of a spontaneous type two BrS ECG pattern and right 
bundle branch block, detected on a 12-lead ECG, in the son. For these reasons, a loop recorder was 
implanted. During the recordings of this device, he experienced an episode of atrioventricular nodal 
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Figure 4. (A) Family pedigree. Proband identified with arrow. Square: male; circle: female; shaded
background: ajmaline positive or spontaneously occurring type one Brugada syndrome (BrS) ECG
pattern; lined bottom left corner: BrS clinically suspected; star: molecularly confirmed SCN5A variant;
star with slash: genetic test for SCN5A variant performed but negative; y: years old at first diagnosis.
(B) Atrioventricular nodal reentrant tachycardia of Patient III-1 detected by loop recorder. (C) Sinus
node arrest associated with syncope in Patient III-1 detected by loop recorder. (D) Sinus node arrest
associated with dizziness during fever in Patient III-1 detected by loop recorder.
The proband’s father (patient I-3 on family tr e, Figure 4A) was a 64-year-old male with a history
of at leas two lipothymic episodes, bradycardia, and an implanted pacemaker before 60 years of
age. He w s evaluated because of t i history and because of the BrS cl nical diagno is in his elder
daughter (the proband). He had a positive result from an ajmaline cha lenge, and genetic testing was
subsequently performed, demonstrating that he was a heterozygous ca rier of the mutation found in
the proband.
The proband’s sister (patient I-5 on Figure 4A) was a 32-year-old woman with no re arkable
medical history. Due to the presence of BrS in her family, she underwent both a flecainide cha lenge
and blood sampling for the genetic test else here. Both tests were negative.
The eldest cousin of the proband (patient I-1) had a edical history characterized by sl ep
disturbances without sl ep apnea, as we l as a single syncopal episode, after which she underwent
genetic co nseling. Genetic tes ing confirmed the presence of th familial mutation in the heterozygous
state with maternal inherit nce. For a seco d opinion, she was evaluated in our hospit l, where an
EPS and ajmaline test were both performed, both with positive results, resulting n th implantation of
an ICD.
The eldest son of patient II-1 was 14 years old. BrS was usp cted due to his mother’ history
of the syndrome combined wi the presence of a spontaneous type two BrS ECG pattern and right
bundle branch block, detected on a 12-lead ECG, in the son. For these reasons, a loop recorder was
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implanted. During the recordings of this device, he experienced an episode of atrioventricular nodal
reentrant tachycardia (Figure 4B), sinus node arrest associated with syncope (Figure 4C), and sinus
node arrest associated with dizziness and a fever of 38.3 ◦C (Figure 4D). For these reasons, an ICD was
implanted. He underwent genetic testing on peripheral blood, which identified the familial variant in
the SCN5A gene.
The second son of patient II-1 was 11 years old. He tested negative for the familial variant, and
the family reported that he was asymptomatic to-date. The third son (from another partner) was six
years old. He experienced a single syncopal episode at the age of four years. He was also affected by
right bundle branch block. Due to this history, he underwent genetic testing, which demonstrated the
presence of the familial heterozygous mutation in the SCN5A gene with maternal inheritance.
Another of the proband’s cousins, patient II-2, was a 35-year-old woman who experienced the first
syncopal episode at the age of 30 years during an at-term delivery. This episode, in association with
family history, prompted genetic testing from peripheral-blood-extracted DNA. This test demonstrated
that she carried the familial NM_198056.2:c.1111C>T (p.Gln371*) heterozygous variant in the SCN5A
gene. After this result, she underwent an EPS procedure elsewhere; during this procedure she
experienced cardiac arrest with electrical cardioversion, followed by ICD implantation. Her sister
(patient II-3) directly requested to undergo a flecainide challenge, which was negative. She also
performed genetic testing with peripheral blood sampling for the familial variant in the SCN5A gene.
This test result was negative as well.
Additional family members were reported to us by our patients, but they were followed at other
centers and did not provide detailed laboratory report information to be included in this case report,
nor did they consent to the use of their personal results for the purposes of publication. Thus, we have
omitted this information.
2.2. In Silico Predictions and Variant Classification
VarSome [22] genetic database, MutationTaster, and FATHMM-MKL were used to clarify the
significance of the SCN5A variant observed in this family. All software supported a damaging effect for
the p.Gln371* variant, with VarSome reporting a pathogenic effect, MutationTaster reporting “disease
causing automatic”, and FATHMM-MKL predicting “damaging”. The Genomic Evolutionary Rate
Profiling (GERP) value was noted, which is defined by VarSome as “a conservation score calculated
by quantifying substitution deficits across multiple alignments of orthologues using the genomes of
35 mammals. It ranges from −12.3 to 6.17, with 6.17 being the most conserved” [23]. The GERP score
for the SCN5A variant described herein was 4.73. According to VarSome, no publications are currently
listed for this variant (last accessed 4 July 2019). The DANN score, which is a pathogenicity-scoring
methodology, ranging from 0 to 1, with 1 given to variants predicted to be the most damaging [24], is
0.9986. The likelihood ratio test (LRT) predicts deleterious variants through the identification of highly
conserved amino acid regions using a comparative genomics data set of 32 vertebrate species, and
ranges from 0 to 1 [22]. The LRT score for this variant was 0, with a deleterious prediction. Regarding
the allele frequency, this variant does not have a gnomAD exomes or genomes entry, but its locus is
covered in the gnomAD exomes (mean coverage = 58.2) and genomes (mean coverage = 33.9) [22].
The c.1111C>T (p.Gln371*) variant was classified as pathogenic according to criteria of the
American College of Medical Genetics and Genomics and the Association for Molecular Pathology [25]:
• PVS1: null variant (nonsense) affecting the SCN5A gene, which is a known mechanism of disease
(385 pathogenic variants out of 749 classified variants = 51.40%, which is greater than threshold
= 10.0%), associated with Brugada syndrome, atrial fibrillation, long QT syndrome type three,
idiopathic ventricular fibrillation, progressive heart block, nonprogressive heart block, sick sinus
syndrome, and dilated cardiomyopathy.
• PM1: UniProt protein SCN5A_HUMAN intra-membrane domain “pore-forming” has seven
pathogenic variants out of nine classified variants = 77.8% (greater than 66.6%).
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• PM2: variant not found in gnomAD exomes (good gnomAD exomes coverage = 58.2). Variant not
found in gnomAD genomes (good gnomAD genomes coverage = 33.9).
• PP3: pathogenic computational verdict because of five pathogenic predictions from DANN, GERP,
LRT, MutationTaster, and FATHMM-MKL (vs. no benign predictions).
3. Discussion
In the present study, we report the novel NM_198056.2:c.1111C>T (p.Gln371*) heterozygous
variant in the SCN5A gene, together with its segregation in a large family, where this variant is
associated with a severe form of BrS. The pathogenicity of this variant is supported by a number
of criteria, including the fact that it is found in a gene that is known to be responsible for various
pathologies, as well as its extreme rarity in the general population, and the unanimous pathogenic in
silico predictions. These results together strongly support a pathogenic role for this variant.
The alpha subunit of the NaV1.5 protein is codified by the SCN5A gene. Pathogenic variations in
this gene result in a wide range of sodium channel dysfunctions. These variants include loss-of-function
of the NaV1.5 protein by either decreased expression of NaV1.5 in the sarcolemma [26], production of
non-functional channels [27], or alterations in gating properties, such as delayed activation, earlier
inactivation, faster inactivation, enhanced slow inactivation, and delayed recovery of NaV1.5 after
inactivation [28,29].
The c.1111C>T variant in the SCN5A gene described herein is a nonsense mutation that introduces
a premature stop codon, which would result in a truncated and incomplete protein product. Previous
cases involving premature stop codons in the SCN5A gene have also suggested a pathogenic role
for nonsense variants resulting in a premature stop of the protein translation [18]. The mutation
c.5464_5467del (reported as L1821fs/10) in the SCN5A gene has been associated with VT, recurrent
aborted sudden death, and BrS [30]. The SCN5A missense and nonsense mutations D1430N and
Q1476X resulted in a complete loss of ventricular Na+ current and were associated in two different
families with Brugada-like ST elevation in the inferior leads or isolated conduction disturbances [31].
The SCN5A mutations Q1832E and R1944X have both been identified in a sudden infant death
victim [32]. A frameshift mutation resulting in a premature stop codon at the C-terminus identified in a
Dutch family was found to result in the translation of a non-functional channel protein that did not reach
the plasma membrane, but rather was retained intracellularly [33]. Similarly, a frameshift mutation
resulting in premature truncation of the protein in a 28-year-old man with monomorphic ventricular
tachycardia and BrS was studied in HEK-293 cells, demonstrating reduced protein expression and
the inability to record current in whole-cell patch clamp experiments [34]. These studies support the
pathogenic prediction for the novel variant described in the current study and enable the diagnosis of
BrS in a carrier even if a drug challenge test has not yet been performed for various reasons (patient’s
age, refusal of the procedure, or travel restrictions).
Many studies have investigated the general role of the SCN5A gene in BrS, but with conflicting
results. In one meta-analysis, BrS patients harboring an SCN5A mutation, with respect to BrS patients
not harboring an SCN5A mutation, generally experienced an earlier onset of symptoms, were more likely
to exhibit a spontaneous type one BrS ECG pattern, had more pronounced conduction or repolarization
abnormalities, had increased atrial vulnerability, and had an increased risk of major arrhythmic events
in Asian and Caucasian populations [35]. However, a standardized bioinformatics re-analysis (SIFT,
PolyPhen, MutationTaster, MutationAssessor, FATHMM, GERP, phyloP, and SiPhy) and re-evaluation
of frequency in the gnomAD database concluded that only a minority of SCN5A variants implicated in
BrS fulfill the criteria for pathogenicity or likely pathogenicity based on contemporary guidelines of the
American College of Medical Genetics and Genomics and the Association for Molecular Pathology [36].
These seemingly conflicting results may be explained by the grouping together of all BrS patients with
SCN5A mutations, regardless of what type of variant was exhibited. Missense, nonsense, splicing,
insertion/deletion, and frameshift mutations may all result in BrS, but alter the NaV1.5 protein in
different ways [4,11], potentially affecting the phenotype of the patient. The importance of the NaV1.5
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protein in BrS is clear, but better understanding the many ways in which it is altered and relating those
different alterations to different severities in phenotypes could be useful.
It must be considered that a nonsense mutation can alter a channel protein more seriously than
some other kinds of mutations. In fact, the NaV1.5 protein displays some domains that are critical for
protein function; one of these is the voltage sensor domain, which is localized close to exon 9, which
maps the mutation described herein [37]. Taken together, all these data provide convincing evidence
that a heterozygous state for the c.1111C>T variant in the SCN5A gene can predispose the carrier to BrS.
Having a clear understanding of genotype–phenotype relationships can assist in the diagnosis of
BrS, enabling faster, easier, and less-invasive testing, and can enable the diagnosis of patients who are
unable to travel or who may refuse ajmaline testing because of fear of the procedure. Additionally,
ajmaline testing is generally not performed on infants and children because of both safety and accuracy
concerns. In one study, repeated ajmaline challenge after puberty unmasked Brugada syndrome in
23% of relatives with a previously negative drug test performed during childhood [38]. Therefore,
ajmaline testing cannot be exclusively relied upon for the diagnosis of children. Thus, maximizing the
use of genetic testing is a significant clinical goal to improve the diagnostic capabilities for all ages, but
especially children and those who are unable to travel.
4. Concluding Remarks
The novel NM_198056.2:c.1111C>T (p.Gln371*) heterozygous variant in the SCN5A gene
segregated with BrS in the large family presented. Taken together, the results strongly suggest
a pathogenic effect of this variant and the usefulness to search for it even in patients who are
asymptomatic at the time of the clinical assessment. Functional studies are certainly warranted to
characterize the molecular effects of this variant, and to improve the usefulness of genetic testing to
identify at-risk family members and implement preventive interventions.
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